Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials

Recent major phase III trials led to the approval of immune checkpoint inhibitors (ipilimumab, pembrolizumab, and nivolumab) in metastatic malignant melanoma (MM). We aim to assess whether median progression-free survival, and 1 and 2-year overall survival (OS) rates are reliable surrogate endpoints...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Fausto, Coinu, Andrea, Cabiddu, Mary, Borgonovo, Karen, Ghilardi, Mara, Lonati, Veronica, Barni, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937921/
https://www.ncbi.nlm.nih.gov/pubmed/27368007
http://dx.doi.org/10.1097/MD.0000000000003997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937921/
https://www.ncbi.nlm.nih.gov/pubmed/27368007
http://dx.doi.org/10.1097/MD.0000000000003997

Ejemplares similares